The Discovery of MK-4256, a Potent SSTR3 Antagonist as a Potential Treatment of Type 2 Diabetes

New Drug Approvals

somatostatin receptor antagonist

C27 H23 F N8 O

494.5229

3(R)-[4-(4-Fluorophenyl)-1H-imidazol-2-yl]-1(R)-(5-methyl-1,2,4-oxadiazol-3-yl)-1-(1-methyl-1H-pyrazol-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
3(R)-[4-(4-Fluorophenyl)-1H-imidazol-2-yl]-1(R)-(5-methyl-1,2,4-oxadiazol-3-yl)-1-(1-methyl-1H-pyrazol-4-yl)-2,3,4,9-tetrahydro-1H-beta-carboline

1H-Pyrido[3,4-b]indole, 3-[5-(4-fluorophenyl)-1H-imidazol-2-yl]-2,3,4,9-tetrahydro-1-(5-methyl-1,2,4-oxadiazol-3-yl)-1-(1-methyl-1H-pyrazol-4-yl)-, (1R,3R)-

3-((1R,3R)-3-(4-(4-fluorophenyl)-1H-imidazol-2-yl)-1-(1-methyl-1H-pyrazol-4-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-5-methyl-1,2,4-oxadiazole

Merck & Co. (Originator)

Somatostatin srif1C (sst3) Antagonists

The Discovery of MK-4256, a Potent SSTR3 Antagonist as a Potential Treatment of Type 2 Diabetes 
(ACS Medicinal Chemistry Letters) Thursday May 10th 2012
Author(s): Shuwen He, Zhixiong Ye, Quang Truong, Shrenik Shah, Wu Du, Liangqin Guo, Peter H. Dobbelaar, Zhong Lai, Jian Liu,Tianying Jian, Hongbo Qi, Raman K. Bakshi, Qingmei Hong, James Dellureficio, Alexander Pasternak, Zhe Feng, Reynalda deJesus, Lihu Yang, Mikhail Reibarkh, Scott A. Bradley, Mark A. Holmes, Richard G. Ball, Rebecca T. Ruck, Mark A. Huffman,Frederick Wong, Koppara Samuel, Vijay B. Reddy, Stan…

View original post 1,766 more words